Figure 2.
Kaplan-Meier analysis of progression-free survival and overall survival from initiation of tyrosine kinase inhibitor with CSF1R inhibition based on RNA expression rank of CSF1R. A. Comparison of median PFS between CSF1R 50-74 percentile (3.75 months) and CSF1R < 50 percentile (4.04 months) showed no difference (P = 0.43). B. Median PFS showed a trend towards worse PFS in patients with CSF1R expression ≥ 75 percentile at 1.74 months compared to 4.04 months for CSF1R < 50 percentile (P = 0.08). C. Median PFS was not statistically different between CSF1R < 50 percentile (4.04 months) and CSF1R ≥ 50 (2.56 months) (P = 0.22). D. OS was compared between CSF1R 50-74 percentile (20.51 months) and CSF1R < 50 percentile (13.25 months) with no statistically significant difference (P = 0.64). E. No statistically significant difference in OS was observed based on CSF1R ≥ 75 percentile compared to CSF1R < 50 percentile (5.26 months vs 13.25 months) (P = 0.35). F. Median OS was not significantly prolonged among patients with CSF1R ≥ 50 percentile treated with a CSF1R inhibitor (20.51 months) compared to CSF1R < 50 percentile (13.25 months), although there was a trend toward a longer OS (P = 0.42). 1(+) indicates censored event.